Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 1, 2003, Pages 80-89

  Yu, Hsi Yu ^a   Ho, Yi Lwun ^a   Chu, Shu Hsun ^b   Chen, Yih Sharng ^a   Wang, Shoei Shen ^a   Lin, Fang Yue ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADOLESCENT; ADULT; AGED; ANIMAL TISSUE; AORTA VALVE; ARTICLE; BIOPROSTHESIS; FEMALE; FOLLOW UP; HEART VALVE SURGERY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTHESIS FAILURE; RHEUMATIC HEART DISEASE; SCHOOL CHILD; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL; SURVIVAL TIME; SWINE; TREATMENT OUTCOME;

EID: 0042343782     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(02)73608-8     Document Type: Article

References (16)

1. van Doorn CA, Stoodley KD, Saunders NR, Nair RU, Davies GA, Watson DA. Mitral valve replacement with the Carpentier-Edwards standard bioprosthesis: performance into the second decade. Eur J Cardiothorac Surg. 1995;9:253-8.
2. Jamieson WR, Munro AI, Miyagishima RT, Allen P, Burr LH, Tyers GF. Carpentier-Edwards standard porcine bioprosthesis: clinical performance to seventeen years. Ann Thorac Surg. 1995;60:999-1006.
3. Edwards TJ, Livesey SA, Simpson IA, Monro JL, Ross JK. Biological valves beyond fifteen years: the Wessex experience. Ann Thorac Surg. 1995;60:S211-5.
4. Fann JI, Miller DC, Moore KA, et al. Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg. 1996;62:1301-11 (discussion 1311-2).
5. Lue HC, Chen CL, Wei H, et al. The natural history of rheumatic fever and rheumatic heart disease in the Orient. Jpn Heart J. 1979;20:237-52.
6. Padmavati S. Rheumatic fever and rheumatic heart disease in developing countries. Bull World Health Organ. 1978;56:543-50.
7. Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM. 1996;89:127-35.
8. Edmunds LH Jr, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. The American Association for Thoracic Surgery, Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Ann Thorac Surg. 1996;62:932-5.
9. Naqvi TZ, Siegel RJ, Buchbinder NA, et al. Echocardiographic and pathologic features of explanted Hancock and Carpentier-Edwards bioprosthetic valves in the mitral position. Am J Cardiol. 1999;84:1422-7.
10. Grunkemeier GL, Anderson RP, Miller DC, Starr A. Time-related analysis of nonfatal heart valve complications - cumulative incidence (actual) versus Kaplan-Meier (actuarial). Circulation. 1997;96(Suppl II):II70-5.
11. Fiane AE, Saatvedt K, Svennevig JL. Carpentier-Edwards bioprosthesis. Experiences of 17 years with analysis of risk factors of early mortality. Scand Cardiovasc J. 1997;31:39-44.
12. Hwang RR, Lai YC, Tsai CH, Lien WP, Lue HC, Hung CR. Rheumatic heart disease in Taiwan. J Formos Med Assoc. 1993;92(Suppl 4):S200-6.
13. John S, Ravikumar E, John CN, Bashi VV. 25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease. Ann Thorac Surg. 2000;69:1167-72.
14. Duran CM, Gometza B, Saad E. Valve repair in rheumatic mitral disease: an unsolved problem. J Card Surg. 1994;9:282-5.
15. Agarwal BL. Rheumatic heart disease unabated in developing countries. Lancet. 1981;2:910-1.
16. Bernal JM, Rabasa JM, Lopez R, Nistal JF, Muniz R, Revuelta JM. Durability of the Carpentier-Edwards porcine bioprosthesis: role of age and valve position. Ann Thorac Surg. 1995;60:S248-52.